ReviewClinical Medicine Insights. Cardiology2016
CETP Inhibition: Past Failures and Future Hopes.
Review in Clinical Medicine Insights. Cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 78 citations in OpenAlex.
- In silico discovery of CETP inhibitors from ZINC15 compounds using docking, ADMET filtering, and molecular dynamics simulations.Research in pharmaceutical sciences · 2026Article
- Article
- Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments.Current atherosclerosis reports · 2024Review
- Identifying the natural products in the treatment of atherosclerosis by increasing HDL-C level based on bioinformatics analysis, molecular docking, and in vitro experiment.Journal of translational medicine · 2023Article
- A decreased level of high-density lipoprotein is a possible risk factor for type 2 diabetes mellitus: A review.Health science reports · 2023Article
- Structure of New Ferroverdins Recruiting Unconventional Ferrous Iron Chelating Agents.Biomolecules · 2022Article
- Serum HDL cholesterol uptake capacity in subjects from the MASHAD cohort study: Its value in determining the risk of cardiovascular endpoints.Journal of clinical laboratory analysis · 2021Article
- Transcriptome prediction performance across machine learning models and diverse ancestries.HGG advances · 2021Article
- Population-Matched Transcriptome Prediction Increases TWAS Discovery and Replication Rate.iScience · 2020Article
- Evaluating the relationship between alcohol consumption, tobacco use, and cardiovascular disease: A multivariable Mendelian randomization study.PLoS medicine · 2020Observational
- NPC1L1 and ABCG5/8 induction explain synergistic fecal cholesterol excretion in ob/ob mice co-treated with PPAR-α and LXR agonists.Molecular and cellular biochemistry · 2020Article
- UnripeNutrients · 2020Article
- Modification of HDL by reactive aldehydes alters select cardioprotective functions of HDL in macrophages.The FEBS journal · 2020Article
- Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2019Article
- A mathematical model to estimate cholesterylester transfer protein (CETP) triglycerides flux in human plasma.BMC systems biology · 2019Article
- Article
- Towards more specific treatment for diabetic dyslipidemia.Current opinion in lipidology · 2018Review
- Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events.Current cardiology reports · 2018Review
- Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease.Molecular and cellular biochemistry · 2018Review
- Primary genetic disorders affecting high density lipoprotein (HDL).Drugs in context · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The atheroprotective role of high-density lipoprotein cholesterol (HDL-C) in cardiovascular disease has been unequivocally established, and epidemiological data have clearly demonstrated a strong inverse relationship between HDL-C levels and the risk of cardiovascular events, which is independent of the low-density lipoprotein cholesterol (LDL-C) levels. Thus, it would be logical to hypothesize that raising HDL-C might potentially lead to a reduction of cardiovascular risk. Cholesteryl ester transfer protein (CETP) promotes the transfer of cholesteryl esters from HDL to very low-density lipoprotein and LDL. Therefore, CETP inhibition raises HDL-C levels and decreases LDL-C levels. The first trials with CETP inhibitors failed to show a reduction in cardiovascular events. However, newer CETP inhibitors with more favorable effects on lipids are presently being tested in clinical trials with the hope that their use may lead to a reduction in cardiovascular risk. This review aims to provide the current evidence regarding CETP inhibition, as well as the clinical and scientific data pertaining to the new CETP inhibitors in development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.